Divi's Laboratories share news, announcements and annual reports
NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap
Divi's Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2003
Last close ₹9,780.00up ₹116.00 (1.20%)BSE ₹9,715.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹9,664.00.
30 Oct: open ₹9,680.00, high ₹9,865.00, low ₹9,621.50
52-week range of traded prices to 30 Oct 2026
₹5,647.50Low, 2 Apr 2026₹9,865.00High, 30 Oct 2026
- Next results date: the board meets on 7 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,59,628 Cr50th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 88.76
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 15.49
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 10,27,38056.5% delivered
Divi's Laboratories share news and announcements
636 announcements, routine notices left out, newest first. Page 7 of 13.
Nov 2017
Oct 2017
31 Oct · Board meeting
31 Oct · Results
Sep 2017
25 Sep · Updates
25 Sep · Meeting
Aug 2017
Jul 2017
22 Jul · Results
Jun 2017
May 2017
26 May · Results
Apr 2017
Mar 2017
24 Mar · Analysts
Feb 2017
4 Feb · Results
Jan 2017
Dec 2016
23 Dec · News Verification
Exchange has sought clarification from Divi's Laboratories Limited with respect to recent news item captioned "Emkay says on Vizag 483 observation: 1. Proper control not being exercised over computer system 2. Facility equipments not maintained to ensure purity quality strength 3. Documentation and records not maintained or inaccurate falsified." In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Nov 2016
12 Nov · Results
Aug 2016
30 Aug · Regulation 44(3) of SEBI (LODR), Reg., 2015
Jul 2016
Jun 2016
7 Jun · Declaration for audit reports with unmodified opinion(s)
May 2016